peptide sciences glp-1 Semaglutide Research | cGMP Quality GLP-1 therapies are booming -
Description
Initially focused on managing type 2 diabetes, it would not be until 2014 that Novo Nordisks introduction of another GLP-1 agonist, Saxenda, marked a pivotal shift towards weight loss
doi: 10.2337/dc22-1148
Suspected adverse reactions should be reported via the Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
These regular touchpoints also create opportunities to discuss complementary aesthetic treatments as patients progress in their weight loss journey.
It compounds existing trends: GLP-1 adoption reinforces several existing shifts: Fewer social drinking occasions Growth in non-alcoholic alternatives Increased health awareness It changes behaviornot just preference: Most alcohol industry changes are substitution-based
Mounjaro is not approved for PCOS or weight loss
